Avizakimab (BOS161721) is a humanized IgG1 monoclonal antibody that targets interleukin-21[1].
References
[1] Hussaini A, et al. A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects. Clin Transl Sci. 2020 Mar;13(2):337-344. DOI:10.1111/cts.12715